Retraction Note: High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience

Affiliations

• ¹ Hepatology, Gastroenterology and Infectious Diseases Department, Faculty of Medicine, Benha University, Benha, Egypt.
• ² Endemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt.
• ³ National Hepatology and Tropical Medicine Research Institute (NHTMRI), Cairo, Egypt.
• ⁴ Tropical Medicine Department, Tanta University, Tanta, Egypt. sherif.abdelbaky@med.tanta.edu.eg.